Medpace Holdings, Inc. provides clinical research-based drug and medical device development services in North America, Europe, and Asia. It offers a suite of services supporting the clinical development process from Phase I to Phase IV in various therapeutic areas. The company also provides clinical development services to the pharmaceutical, biotechnology, and medical device industries; and development plan design, coordinated central laboratory, project management, regulatory affairs, clinical monitoring, data management and analysis, pharmacovigilance new drug application submissions, and post-marketing clinical support services. In addition, it offers bio-analytical laboratory services, clinical human pharmacology, imaging services, and electrocardiography reading support for clinical trials. The company was founded in 1992 and is based in Cincinnati, Ohio.
Wall Street Analyst Weigh In
A number of research analysts recently weighed in on MEDP shares. StockNews.com raised shares of Medpace from a "hold" rating to a "buy" rating in a research report on Thursday, July 28th. Guggenheim initiated coverage on shares of Medpace in a research report on Monday, May 23rd. They set a "neutral" rating on the stock.
Medpace Stock Performance
MEDP Stock traded down $4.49 during mid-day trading on Wednesday, hitting $176.83. The company had a trading volume of 186,262 shares, compared to its average volume of 339,625. The firm has a market cap of $5.48 billion, a PE ratio of 30.70 and a beta of 1.43. Medpace has a 12 month low of $126.94 and a 12 month high of $231.00. The stock's fifty day moving average price is $155.55 and its two-hundred day moving average price is $152.90.
Medpace (NASDAQ:MEDP - Get Rating) last announced its quarterly earnings data on Monday, July 25th. The company reported $1.46 EPS for the quarter, topping the consensus estimate of $1.33 by $0.13. The business had revenue of $351.21 million for the quarter, compared to analyst estimates of $344.01 million. Medpace had a net margin of 16.27% and a return on equity of 30.56%. The company's revenue for the quarter was up 26.2% on a year-over-year basis. During the same quarter in the previous year, the firm posted $1.06 earnings per share. Equities analysts anticipate that Medpace will post 6.16 earnings per share for the current year.
Insiders Place Their Bets
In related news, CEO August J. Troendle acquired 8,330 shares of the stock in a transaction on Monday, July 18th. The shares were acquired at an average price of $145.00 per share, with a total value of $1,207,850.00. Following the completion of the transaction, the chief executive officer now owns 5,513,639 shares in the company, valued at approximately $799,477,655. The purchase was disclosed in a document filed with the SEC, which is accessible through this hyperlink. In other Medpace news, CEO August J. Troendle purchased 22,290 shares of the stock in a transaction dated Thursday, July 14th. The shares were bought at an average price of $144.59 per share, with a total value of $3,222,911.10. Following the completion of the transaction, the chief executive officer now directly owns 5,505,309 shares in the company, valued at approximately $796,012,628.31. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, CEO August J. Troendle purchased 8,330 shares of the stock in a transaction dated Monday, July 18th. The stock was acquired at an average cost of $145.00 per share, for a total transaction of $1,207,850.00. Following the transaction, the chief executive officer now owns 5,513,639 shares of the company's stock, valued at $799,477,655. The disclosure for this purchase can be found here. Insiders own 20.60% of the company's stock.
